Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bodh I Jugdutt

Showing results (1-10 of 68) with videos related to

Pageof 7
Sort By:
Current Drug Targets|April 9, 2008
Aging and remodeling during healing of the wounded heart: current therapies and novel drug targetsBodh I Jugdutt
Current Drug Targets. Cardiovascular & Haematological Disorders|May 29, 2003
Remodeling of the myocardium and potential targets in the collagen degradation and synthesis pathwaysBodh I Jugdutt
Current Heart Failure Reports|March 7, 2009
Current and novel cardiac support therapiesBodh I Jugdutt
Heart Failure Reviews|January 25, 2012
Prevention of heart failure in the elderly: when, where and how to begin?Bodh I Jugdutt
Circulation|September 17, 2003
Ventricular remodeling after infarction and the extracellular collagen matrix: when is enough enough?Bodh I Jugdutt
Clinical Interventions in Aging|December 15, 2010
Clinical effectiveness of telmisartan alone or in combination therapy for controlling blood pressure and vascular risk in the elderlyBodh I Jugdutt
Cardiovascular Drugs and Therapy|July 16, 2015
Suppression of Ventricular Arrhythmias After Myocardial Infarction by AT1 Receptor Blockade: Role of the AT2 Receptor and Casein Kinase 2/Kir2.1 Pathway. Editorial to: "Valsartan Upregulates Kir2.1 in Rats Suffering from Myocardial Infarction Via Casein Kinase 2" by Xinran Li et alBodh I Jugdutt
Vascular Health and Risk Management|February 27, 2007
Valsartan in the treatment of heart attack survivorsBodh I Jugdutt
Experimental and Clinical Cardiology|July 31, 2009
Apoptosis after reperfused myocardial infarction: Role of angiotensin IIBodh I Jugdutt
The New England Journal of Medicine|April 10, 2009
Limiting fibrosis after myocardial infarctionBodh I Jugdutt
Pageof 7

Showing results (1-10 of 68) with videos related to

Sort By:
Pageof 7
Current Drug Targets|April 9, 2008
Aging and remodeling during healing of the wounded heart: current therapies and novel drug targetsBodh I Jugdutt
Current Drug Targets. Cardiovascular & Haematological Disorders|May 29, 2003
Remodeling of the myocardium and potential targets in the collagen degradation and synthesis pathwaysBodh I Jugdutt
Current Heart Failure Reports|March 7, 2009
Current and novel cardiac support therapiesBodh I Jugdutt
Heart Failure Reviews|January 25, 2012
Prevention of heart failure in the elderly: when, where and how to begin?Bodh I Jugdutt
Circulation|September 17, 2003
Ventricular remodeling after infarction and the extracellular collagen matrix: when is enough enough?Bodh I Jugdutt
Clinical Interventions in Aging|December 15, 2010
Clinical effectiveness of telmisartan alone or in combination therapy for controlling blood pressure and vascular risk in the elderlyBodh I Jugdutt
Cardiovascular Drugs and Therapy|July 16, 2015
Suppression of Ventricular Arrhythmias After Myocardial Infarction by AT1 Receptor Blockade: Role of the AT2 Receptor and Casein Kinase 2/Kir2.1 Pathway. Editorial to: "Valsartan Upregulates Kir2.1 in Rats Suffering from Myocardial Infarction Via Casein Kinase 2" by Xinran Li et alBodh I Jugdutt
Vascular Health and Risk Management|February 27, 2007
Valsartan in the treatment of heart attack survivorsBodh I Jugdutt
Experimental and Clinical Cardiology|July 31, 2009
Apoptosis after reperfused myocardial infarction: Role of angiotensin IIBodh I Jugdutt
The New England Journal of Medicine|April 10, 2009
Limiting fibrosis after myocardial infarctionBodh I Jugdutt
Pageof 7